摘要
目的分析卡格列净与厄贝沙坦对早期糖尿病肾病患者氧化应激状况的影响,并观察患者肾功能变化情况。方法将2022年6月至2024年2月间本院收治早期糖尿病肾病患者纳为对象,共计纳取120例。所选患者被随机分为观察组、对照组,每组纳入60例。观察组以卡格列净与厄贝沙坦结合方案进行治疗,对照组仅采用厄贝沙坦进行治疗。围绕患者氧化应激指标、肾功能指标以及尿蛋白情况变化展开对比,统计患者疗效评价结果与治疗期间不良反应发生情况。结果观察组经治疗干预后,患者的ROS表达水平与8-OHdG表达水平相较于对照组更低,MDA表达水平与对照组相比更高,患者肾功能指标SCr与Ccr水平的改善幅度均高于对照组,24h尿蛋白定量与尿微量白蛋白排泄率对比结果更低,疗效评价对比结果为观察组的总有效率更高。以上研究结果均具有统计学意义(P<0.05)。在治疗期间患者不良反应的总发生情况上,两组的组件对比结果无明显差异(P>0.05)。结论对早期糖尿病肾病患者实施卡格列净与厄贝沙坦联合治疗,能有效缓解患者机体的氧化应激反应,并在改善肾功能方面具有可靠表现,在保障患者疗效的同时,不会增加不良反应发生风险,具有可靠的用药安全性。
Objective To analyze the effects of caglipzin and irbesartan on oxidative stress in early diabetic nephropathy patients,and to observe the changes of renal function.Methods A total of 120 patients with early diabetic nephropathy admitted to our hospital from June 2022 to February 2024 were enrolled.The selected patients were randomly divided into observation group and control group,with 60 cases in each group.The observation group was treated with the combination regimen of caglipzin and irbesartan,while the control group was treated with irbesartan only.The oxidative stress index,renal function index and urinary protein of patients were compared,and the results of therapeutic effect evaluation and the occurrence of adverse reactions during treatment were counted.Results After treatment and intervention,ROS expression level and 8-OHdG expression level of patients in the observation group were lower than those in the control group,MDA expression level was higher than that in the control group,SCr and Ccr levels of patients with renal function indexes were improved more than those in the control group,and the comparison result of 24h urinary protein quantification and urinary microalbumin excretion rate was lower.The comparison result of curative effect evaluation was that the total effective rate of the observation group was higher.The above results were statistically significant(P<0.05).There was no significant difference in the total occurrence of adverse reactions between the two groups(P>0.05).Conclusion The combination therapy of caglipzin and irbesartan in early diabetic nephropathy patients can effectively alleviate the oxidative stress response of the patients,and has a reliable performance in improving renal function.While ensuring the efficacy of patients,it will not increase the risk of adverse reactions,and has a reliable drug safety.
作者
樊新成
张将军
张慧敏
FAN Xin-cheng;ZHANG Jiang-jun;ZHANG Hui-min(Department of Nephrology,Xiangcheng Hospital of Traditional Chinese Medicine,Xiangcheng 466200,Henan Province,China)
出处
《罕少疾病杂志》
2026年第2期94-96,107,共4页
Journal of Rare and Uncommon Diseases
基金
河南医学科技攻关计划联合共建项目(LHGJ20203037)。
关键词
早期糖尿病肾病
卡格列净
厄贝沙坦
氧化应激
肾功能
Early Diabetic Nephropathy
Calaglizin
Lrbesartan
Oxidative Stress
Renal Function
